Beacon Therapeutics Secures $170 Million in Series B Funding
Key Highlights $170 million raised in Series B funding led by Forbion. Funds to support AGTC-501 clinical trials for X-Linked Retinitis Pigmentosa (XLRP).…
Browsing Tag
Oxford Science Enterprises
1 post